Biopharma | January 07, 2026
Medera doses final patient in high-dose HFpEF gene therapy trial
Heart failure affects an estimated 64.3 million people worldwide
Heart failure affects an estimated 64.3 million people worldwide
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
Pravesh brings with him over 29 years of experience in leading complex manufacturing operations and driving operational excellence
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
The FDA acknowledged that Corcept’s pivotal GRACE trial met its primary endpoint and that data from the GRADIENT trial offered confirmatory evidence
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Subscribe To Our Newsletter & Stay Updated
